ALGS Posts Aligos Therapeutics

7/7/2026 12:42:01 AM

ALGS #AligosTherapeutics stock increases 12.5% after hours.

After Hours Gainer

ALGS Aligos Therapeutics5.85+0.26+4.7%

After Hours:6.58+0.73 (+12.5%)

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Globe NewswireMon, 6-Jul 4:05 PM

7/6/2026 4:54:04 PM

ALGS #AligosTherapeutics stock increases 18.8% after hours.

After Hours Gainer

ALGS Aligos Therapeutics5.85+0.26+4.7%

After Hours:6.95+1.10 (+18.8%)

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Globe NewswireMon, 6-Jul 4:05 PM

11/6/2024 10:08:06 AM

Upcoming Earnings

ALGS Aligos Therapeutics9.80-0.03 (-0.3%)

Aligos Therapeutics will report earnings after the market closes. View Calendar The market is expecting a ±25.7% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±6.0%. View Expected Move

9/19/2024 8:54:56 AM

ALGS #AligosTherapeutics stock declines -14.2% in premarket,

Premarket Decliner

ALGS Aligos Therapeutics14.16-0.23-1.6%

Premarket:12.15-2.01 (-14.2%)

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Globe NewswireThu, 19-Sep 8:00 AM

9/19/2024 12:40:55 AM

ALGS #AligosTherapeutics stock increases 9.5% after hours.

After Hours Gainer

ALGS Aligos Therapeutics14.16-0.23-1.6%

After Hours:15.50+1.34 (+9.5%)

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Globe NewswireWed, 18-Sep 5:00 PM

9/18/2024 8:20:08 PM

ALGS #AligosTherapeutics stock increases 9.5% after hours.

After Hours Gainer

ALGS Aligos Therapeutics14.16-0.23-1.6%

After Hours:15.50+1.34 (+9.5%)

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Globe NewswireWed, 18-Sep 5:00 PM

ALGS Stock Posts